Boca Raton, Fl -- (SBWIRE) -- 11/27/2012 -- Acadia Pharmaceuticals has just announced huge results in it’s phase 3 trail drug Pimavanserin. The company has reported that the drug meets the Primary and secondary end points in phase III of trial. The stock is up on premarket activity 171%. Read the full press release at http://www.sbwire.com/press-releases/sbwire-183208.htm